WO2023076418A3 - Platforms, compositions, and methods for therapeutic delivery - Google Patents

Platforms, compositions, and methods for therapeutic delivery Download PDF

Info

Publication number
WO2023076418A3
WO2023076418A3 PCT/US2022/047925 US2022047925W WO2023076418A3 WO 2023076418 A3 WO2023076418 A3 WO 2023076418A3 US 2022047925 W US2022047925 W US 2022047925W WO 2023076418 A3 WO2023076418 A3 WO 2023076418A3
Authority
WO
WIPO (PCT)
Prior art keywords
extracellular vesicle
methods
compositions
platforms
therapeutic delivery
Prior art date
Application number
PCT/US2022/047925
Other languages
French (fr)
Other versions
WO2023076418A2 (en
Inventor
Charles Cameron TAYLOR
Milad Riazifar
Todd SCHURR
Original Assignee
Entelexo Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelexo Biotherapeutics, Inc. filed Critical Entelexo Biotherapeutics, Inc.
Publication of WO2023076418A2 publication Critical patent/WO2023076418A2/en
Publication of WO2023076418A3 publication Critical patent/WO2023076418A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed herein is an engineered extracellular vesicle and compositions containing the engineered extracellular vesicle. Further disclosed are methods of manufacturing and administering the engineered extracellular vesicle and compositions containing said engineered extracellular vesicle. Further, wherein a composition comprises an extracellular vesicle, wherein the extracellular vesicle comprises a transmembrane moiety bound to an affinity receiver.
PCT/US2022/047925 2021-10-26 2022-10-26 Platforms, compositions, and methods for therapeutic delivery WO2023076418A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163272059P 2021-10-26 2021-10-26
US63/272,059 2021-10-26
US202263354613P 2022-06-22 2022-06-22
US63/354,613 2022-06-22

Publications (2)

Publication Number Publication Date
WO2023076418A2 WO2023076418A2 (en) 2023-05-04
WO2023076418A3 true WO2023076418A3 (en) 2023-11-02

Family

ID=86158728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/047925 WO2023076418A2 (en) 2021-10-26 2022-10-26 Platforms, compositions, and methods for therapeutic delivery

Country Status (1)

Country Link
WO (1) WO2023076418A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023076418A2 (en) * 2021-10-26 2023-05-04 Entelexo Biotherapeutics, Inc. Platforms, compositions, and methods for therapeutic delivery
WO2023250440A1 (en) * 2022-06-22 2023-12-28 Entelexo Biotherapeutics, Inc. Engineered extracellular vesicles for therapeutic delivery

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160884A1 (en) * 2016-03-14 2017-09-21 Capricor, Inc. Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
US10527609B2 (en) * 2010-02-11 2020-01-07 Oxford University Innovation Limited Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
WO2020257710A1 (en) * 2019-06-21 2020-12-24 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
WO2021154888A1 (en) * 2020-01-27 2021-08-05 Mantra Bio. Inc. Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof
WO2023076418A2 (en) * 2021-10-26 2023-05-04 Entelexo Biotherapeutics, Inc. Platforms, compositions, and methods for therapeutic delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10527609B2 (en) * 2010-02-11 2020-01-07 Oxford University Innovation Limited Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
WO2017160884A1 (en) * 2016-03-14 2017-09-21 Capricor, Inc. Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
WO2020257710A1 (en) * 2019-06-21 2020-12-24 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
WO2021154888A1 (en) * 2020-01-27 2021-08-05 Mantra Bio. Inc. Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof
WO2023076418A2 (en) * 2021-10-26 2023-05-04 Entelexo Biotherapeutics, Inc. Platforms, compositions, and methods for therapeutic delivery

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTHONY H. KEEBLE, PAULA TURKKI, SAMUEL STOKES, IRSYAD N. A. KHAIRIL ANUAR, ROLLE RAHIKAINEN, VESA P. HYTöNEN, MARK HOWARTH: "Approaching infinite affinity through engineering of peptide–protein interaction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 116, no. 52, 26 December 2019 (2019-12-26), pages 26523 - 26533, XP055723018, ISSN: 0027-8424, DOI: 10.1073/pnas.1909653116 *
CHAUHAN VEEREN M.; ZHANG HONGYU; DALBY PAUL A.; AYLOTT JONATHAN W.: "Advancements in the co-formulation of biologic therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 327, 14 August 2020 (2020-08-14), AMSTERDAM, NL , pages 397 - 405, XP086327830, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2020.08.013 *
KANG HAE JOO, PATERSON NEIL G., GASPAR ANDREW H., TON-THAT HUNG, BAKER EDWARD N.: "The Corynebacterium diphtheriae shaft pilin SpaA is built of tandem Ig-like modules with stabilizing isopeptide and disulfide bonds", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 40, 6 October 2009 (2009-10-06), pages 16967 - 16971, XP093107520, ISSN: 0027-8424, DOI: 10.1073/pnas.0906826106 *
WENDY FITZGERALD, GOMEZ-LOPEZ NARDHY, EREZ OFFER, ROMERO ROBERTO, MARGOLIS LEONID: "Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 80, no. 1, 1 July 2018 (2018-07-01), US , pages e12860, XP055547900, ISSN: 1046-7408, DOI: 10.1111/aji.12860 *

Also Published As

Publication number Publication date
WO2023076418A2 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
WO2023076418A3 (en) Platforms, compositions, and methods for therapeutic delivery
WO2009095479A3 (en) Prodrug comprising a self-cleavable linker
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
WO2003027076A3 (en) 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
AU743229C (en) Transdermal therapeutic system containing pergolide
WO2008081399A3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
MX2014001556A (en) Taste masked pharmaceutical composition.
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
WO2006117220A3 (en) Method of administering a cationic liposomal preparation comprising paclitaxel
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2008037484A3 (en) Formulations comprising cyclic compounds
TW200612976A (en) Peptidic vasopressin receptor agonists
WO2006042954A8 (en) 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof
WO2003000709A3 (en) Sialic acid derivatives for use as siglec inhibitors
WO2005113012A3 (en) Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
AU2002353775A1 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
EP2308479A3 (en) Compounds and compositions for delivering active agents
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
WO2009093264A3 (en) Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
WO2007064620A3 (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists
WO2002009639A3 (en) Methods and pharmaceutical compositions for healing wounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22888137

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE